Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group trial

S. D. Williams, R. Birch, L. H. Einhorn

Research output: Contribution to journalArticle

99 Scopus citations

Abstract

Twenty-two evaluable patients with all cell types of advanced thyroid cancer were treated with the combination of doxorubicin (60 mg/m2) plus cisplatin (60 mg/m2). There were two brief partial remissions (9.1%). There was considerable toxicity, with one drug-related death. Combination chemotherapy as given in this study was not effective for this patient population.

Original languageEnglish (US)
Pages (from-to)405-407
Number of pages3
JournalCancer Treatment Reports
Volume70
Issue number3
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group trial'. Together they form a unique fingerprint.

  • Cite this